Zai Lab (ZLAB) Earnings Dates, Call Summary & Reports

Compare

708 Followers

Earnings Data

Report Date

May 12, 2026

TBA (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.39

Last Year’s EPS

-0.45

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 4 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 26, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed strong operational and R&D momentum: double-digit revenue growth (Q4 +17%, FY +15%), a solid cash balance ($790M), improved operating leverage (R&D -6%, SG&A -12% Q4 / -7% FY), and rapid advancement of high-impact global programs (notably zoci's rapid move to Phase III and encouraging intracranial activity). Management also outlined several near-term commercial launches and late-stage regional catalysts. Offsetting these positives were near-term commercial and pricing headwinds (NRDL renewal effects, hospital procurement timing), supply constraints earlier in the year, generic competition in certain categories, and some uncertainty around 2026 guidance and regulatory/enrollment timing for global registrational programs. On balance, the highlights—particularly the strong financial momentum, large pipeline milestones, and robust cash runway—substantially outweigh the lowlights, though execution and regulatory risks remain.

Company Guidance

Management framed 2026 as a year of execution and preparation and gave several quantitative guideposts: Q4 revenue was $127.6M (+17% YoY) and full‑year 2025 revenue was $460.2M (+15% YoY); R&D expense declined 6% YoY, SG&A fell 12% in Q4 and 7% for the full year, loss from operations improved 19% to $229.4M (improving 25% on an adjusted basis excluding non‑cash items), and cash totaled $790M at year‑end. They did not provide full‑year 2026 revenue guidance because of moving pieces (VYVGART IV price adjustment, rebate dynamics and hospital purchasing), but expect measured near‑term growth from VYVGART, continued strength in ZEJULA and XACDURO, and planned launches (KarXT commercial launch/COBENFY in Q2 2026; TIVDAK later in 2026) with modest incremental SG&A for launches and R&D broadly stable. Key clinical milestones and timelines included zoci moving from IND to global Phase III in <2 years with a ~480‑patient registrational study (China ~1/3, U.S. ~30%), an 80% ORR reported in 10 patients with untreated brain mets, plans for a potential accelerated submission in 2027 and first global approval in 2028 plus a first‑line pivotal study this year; additional 2026 catalysts cited were zoci data in brain mets/NEC/1L SCLC, first‑in‑human ZL‑1503 data, a povetacicept interim for IgAN in H1 2026, REVEAL‑1 topline in Q1 2026 and REVEAL‑2 in Q2 2026, and expected China approval for TIVDAK in H1 2026.

Revenue Growth (Q4 and Full Year 2025)

Fourth quarter total revenue of $127.6M, up 17% year-over-year; full year 2025 total revenue of $460.2M, up 15% year-over-year.

Strong Cash Position

Ended the quarter with $790M in cash, supporting near-term launches and global R&D investment.

Improved Operating Leverage and Expense Discipline

R&D expenses declined 6% year-over-year for the full year; SG&A expenses decreased 12% in Q4 and 7% for the full year. Loss from operations improved 19% to $229.4M and improved 25% on an adjusted (ex-noncash) basis.

Commercial Product Strength (XACDURO, NUZYRA, ZEJULA)

XACDURO and NUZYRA were cited as strong contributors to Q4 revenue. ZEJULA delivered a strong Q4 driven by first-line BRCA-positive new patient starts. XACDURO saw strong patient demand and expanding hospital adoption despite earlier supply constraints.

VYVGART Market Progress

Physician confidence and patient demand for VYVGART remain stable. Average cycles per patient improved >50% versus 2024 by year-end, with management targeting a guideline-supported minimum of 3 cycles per patient as a near-term objective.

Rapid Global R&D Progress — zoci (DLL3 ADC)

zoci advanced from IND to global registrational Phase III in less than 2 years. Global Phase III in 2L/3L SCLC initiated (approx. 480 patients). Clinical signals include an 80% objective response rate in 10 patients with untreated brain metastases; favorable safety profile with low rates of severe TRAEs. Management expects a potential accelerated approval submission in 2027 and first global approval in 2028 (subject to timelines).

Broader Innovation Pipeline Momentum

Multiple programs advanced: ZL-6201 (LRRC15 ADC) received U.S. IND clearance and initiated global Phase I; ZL-1222 (PD-1/IL-12) in IND-enabling studies; ZL-1311 (MUC17 TCE) IND planned by year-end; ZL-1503 (IL-13/IL-31 bispecific) Phase I/Ib enrolling with first-in-human data expected later this year.

Late-Stage Regional Catalysts

Povetacicept interim analysis for the global RAINIER Phase III in IgAN planned in H1 2026; elegrobart global REVEAL-1 top-line in Q1 2026 and REVEAL-2 in Q2 2026; efgartigimod continuing label-expansion efforts across autoimmune indications.

Product Approvals and Upcoming Launches

TIVDAK expected to be approved in China in H1 2026; COBENFY commercial launch planned in Q2 2026; KarXT commercial launch planned in Q2 2026 (NRDL expected in 2027). FDA approval of Optune Pax for locally advanced pancreatic cancer achieved earlier in the month.

Zai Lab (ZLAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZLAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 12, 2026	2026 (Q1)	-0.39 / -	-0.45	―	―	―
Feb 26, 2026	2025 (Q4)	-0.36 / -0.46	-0.8	42.50% (+0.34)
Nov 06, 2025	2025 (Q3)	-0.29 / -0.33	-0.42	21.43% (+0.09)
Aug 07, 2025	2025 (Q2)	-0.36 / -0.37	-0.82	54.88% (+0.45)
May 08, 2025	2025 (Q1)	-0.55 / -0.45	-0.55	18.18% (+0.10)
Feb 27, 2025	2024 (Q4)	-0.65 / -0.80	-1.63	50.92% (+0.83)
Nov 12, 2024	2024 (Q3)	-0.78 / -0.42	-0.07	-500.00% (-0.35)
Aug 06, 2024	2024 (Q2)	-0.71 / -0.82	-1.25	34.40% (+0.43)
May 08, 2024	2024 (Q1)	-0.93 / -0.55	-0.51	-7.84% (-0.04)	―
Feb 27, 2024	2023 (Q4)	-0.86 / -1.63	-0.65	-150.77% (-0.98)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ZLAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$24.80	$23.15	-6.65%
Aug 07, 2025	$38.72	$34.08	-11.98%
May 08, 2025	$28.36	$29.14	+2.75%
Feb 27, 2025	$35.07	$34.38	-1.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zai Lab (ZLAB) report earnings?

Zai Lab (ZLAB) is schdueled to report earning on May 12, 2026, TBA (Confirmed).

What is Zai Lab (ZLAB) earnings time?

Zai Lab (ZLAB) earnings time is at May 12, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZLAB EPS forecast?

ZLAB EPS forecast for the fiscal quarter 2026 (Q1) is -0.39.